



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application:

I. Campbell et al.,

Serial No.: 09/830,836

Examiner: B. Robinson

Filing Date: 1 May 2001

Art Unit: 1625

For: PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

#17
5/7/03Assistant Commissioner of Patents
Washington D.C. 20231LETTER TO THE EXAMINER

Sir:

Applicants hereby wish to notify the Examiner of the following co-pending applications:

10/212,513 filed 8/5/02
10/212,514 filed 8/5/02
10/258,679 filed 10/25/02
10/168,002 filed 6/14/02 (allowed)
10/001,600 filed 10/31/02**RECEIVED**

MAY 05 2003

TECH CENTER 1600/2900

and the following patent:

US Patent No. 6,451,794 granted 9/17/02 and 6,498,166 granted 12/24/02

The foregoing applications and patents have different inventive entities from the present application but are all commonly assigned.

Respectfully submitted,

Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181Date: 15 April, 2003
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222/fax: (919) 483-7988

FIRST CLASS



FIRST CLASS

FIRST CLASS

FIRST CLASS

FIRST CLASS

FIRST CLASS



FIRST CLASS MAIL



GlaxoSmithKline

Corporate Intellectual Prop.

MAI-B.475.4D

GlaxoSmithKline
Five Moore Drive
PO Box 13398
Research Triangle Park NC 27709-3398

Sender: _____

Extension: _____

Cost Center: _____

*Returned from
post office
4/30/03.
Resent 4/30/03*

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, DC 20231



RECEIVED

MAY 05 2003

TECH CENTER 1600/2900

FIRST CLASS

FIRST CLASS

FIRST CLASS

FIRST CLASS